Feed CTRE
CT

CareTrust REIT, Inc. CTRE · NYSE

$35.86 -1.89% (-$0.69)

Summary

81 / 100 · Bulios Score

What speaks for it

  • Earnings per share grew by 53% a year over the last 3 years.
  • Out of every 100 USD of revenue, 65 USD is left as net profit.
  • It earns 6.5 USD a year on every 100 USD of invested capital.
  • It has raised its dividend 6 years in a row.

What to watch

None of the indicators we track raises a caution right now.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced
Bulios Fair Price
Current price $35.86
5-year average P/E 32.8 27% lower
P/E today 23.8
REIT - Healthcare Facilities industry median
P/E today 23.8

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 23.8 USD for 1 USD of yearly profit. Over the last five years it was 32.8 USD on average.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 22% a year over 5 years. Over the last 3 years it grew by 36% a year. Earnings per share grew by 53% a year over the last 3 years.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (REIT - Healthcare Facilities) 11 USD

Out of every 100 USD of revenue, 65 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

Repaying all its debt would take 2.8 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

Moderate, stretched
Yield
4.20%
Paid out of profit
100%
Raised in a row
6 years

You receive $1.50 per share a year. The payout takes a large part of its profit or free cash flow.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $44 is 23% above today's price. 68% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

The company reports no revenue by region.

Reportable Segment brings in 100% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.